Literature DB >> 24251710

Role of diet and nutritional management in non-alcoholic fatty liver disease.

Jian-Gao Fan1, Hai-Xia Cao.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum ranging from simple steatosis to non-alcoholic steatohepatitis, which causes an increased risk of cirrhosis, type 2 diabetes, and cardiovascular complications. With the worldwide growing incidence of obesity, sedentary lifestyle, and unhealthy dietary pattern, NAFLD has currently been recognized as a major health burden. Dietary patterns and nutrients are the important contributors to the development, progression, and treatment of NAFLD and associated metabolic comorbidities. Generally, hypercaloric diet, especially rich in trans/saturated fat and cholesterol, and fructose-sweetened beverages seem to increase visceral adiposity and stimulate hepatic lipid accumulation and progression into non-alcoholic steatohepatitis, whereas reducing caloric intake, increasing soy protein and whey consumption, and supplement of monounsaturated fatty acids, omega-3 fatty acids, and probiotics have preventive and therapeutic effects. In addition, choline, fiber, coffee, green tea, and light alcohol drinking might be protective factors for NAFLD. Based on available data, at least 3-5% of weight loss, achieved by hypocaloric diet alone or in conjunction with exercise and behavioral modification, generally reduces hepatic steatosis, and up to 10% weight loss may be needed to improve hepatic necroinflammation. A sustained adherence to diet rather than the actual diet type is a major predictor of successful weight loss. Moreover, a healthy diet has benefits beyond weight reduction on NAFLD patients whether obese or of normal weight. Therefore, nutrition serves as a major route of prevention and treatment of NAFLD, and patients with NAFLD should have an individualized diet recommendation.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  NAFLD/NASH; diet; fatty liver; nutrition; obesity

Mesh:

Year:  2013        PMID: 24251710     DOI: 10.1111/jgh.12244

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  44 in total

Review 1.  Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease.

Authors:  William N Hannah; Stephen A Harrison
Journal:  Dig Dis Sci       Date:  2016-05       Impact factor: 3.199

2.  Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease.

Authors:  Vanessa Souza-Mello
Journal:  World J Hepatol       Date:  2015-05-18

Review 3.  Preclinical models of non-alcoholic fatty liver disease.

Authors:  Prasanna K Santhekadur; Divya P Kumar; Arun J Sanyal
Journal:  J Hepatol       Date:  2017-11-09       Impact factor: 25.083

Review 4.  Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective.

Authors:  Becky Ching-Yeung Yu; Deborah Kwok; Vincent Wai-Sun Wong
Journal:  J Clin Exp Hepatol       Date:  2019-02-07

5.  The relationship between sugar-sweetened beverages and liver enzymes among healthy premenopausal women: a prospective cohort study.

Authors:  Maya K Shimony; Karen C Schliep; Enrique F Schisterman; Katherine A Ahrens; Lindsey A Sjaarda; Yaron Rotman; Neil J Perkins; Anna Z Pollack; Jean Wactawski-Wende; Sunni L Mumford
Journal:  Eur J Nutr       Date:  2015-03-24       Impact factor: 5.614

Review 6.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

Review 7.  Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet.

Authors:  Ludovico Abenavoli; Natasa Milic; Valentina Peta; Francesco Alfieri; Antonino De Lorenzo; Stefano Bellentani
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice.

Authors:  Nisreen Soufi; Angela M Hall; Zhouji Chen; Jun Yoshino; Sara L Collier; James C Mathews; Elizabeth M Brunt; Carolyn J Albert; Mark J Graham; David A Ford; Brian N Finck
Journal:  J Biol Chem       Date:  2014-09-11       Impact factor: 5.157

Review 9.  Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development.

Authors:  Pau Vancells Lujan; Esther Viñas Esmel; Emilio Sacanella Meseguer
Journal:  Nutrients       Date:  2021-04-24       Impact factor: 5.717

10.  Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.

Authors:  Shang-Chin Huang; Hau-Jyun Su; Jia-Horng Kao; Tai-Chung Tseng; Hung-Chih Yang; Tung-Hung Su; Pei-Jer Chen; Chun-Jen Liu
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.